Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Anixa Biosciences Inc. (ANIX:NASDAQ), powered by AI.
Anixa Biosciences Inc. is currently trading at $2.47. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Anixa Biosciences Inc. on Alpha Lenz.
Anixa Biosciences Inc.'s P/E ratio is -7.3.
“Anixa Biosciences Inc. trades at a P/E of -7.3 (undervalued) with modest ROE of -62.2%.”
Ask for details →Anixa Biosciences Inc. is a biotechnology company primarily engaged in the innovative development of cancer therapies and infectious disease solutions. With a focus on disruptive healthcare technologies, Anixa aims to revolutionize treatment modalities through unique scientific approaches and strategic collaborations. One of the company’s notable endeavors lies in immuno-oncology, where it explores novel methods to harness the body's immune system to combat cancer. Additionally, Anixa is active in the field of diagnosis and prevention, developing advanced diagnostic tools to enhance early detection and intervention strategies. The company’s work extends across various healthcare sectors, impacting both cancer research and public health initiatives. Operating at the forefront of biotechnology, Anixa Biosciences Inc. plays a significant role in the ongoing advancement of medical sciences, striving to deliver breakthroughs that could reshape standard healthcare practices. Its commitment to innovation positions it as a dynamic player in the biopharmaceutical landscape, contributing to crucial developments in therapeutic and diagnostic technologies.
“Anixa Biosciences Inc. trades at a P/E of -7.3 (undervalued) with modest ROE of -62.2%.”
Ask for details →Anixa Biosciences Inc. (ticker: ANIX) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 5 employees. Market cap is $80M.
The current price is $2.47 with a P/E ratio of -7.34x and P/B of 5.29x.
ROE is -62.16%.